Twist Bioscience (NASDAQ:TWST) and Cellular Biomedicine Group (NASDAQ:CBMG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
This table compares Twist Bioscience and Cellular Biomedicine Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Biomedicine Group||-17,386.16%||-42.82%||-40.08%|
Valuation and Earnings
This table compares Twist Bioscience and Cellular Biomedicine Group’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Twist Bioscience||$25.43 million||31.51||-$71.23 million||($25.51)||-1.12|
|Cellular Biomedicine Group||$220,000.00||1,438.98||-$38.93 million||($2.04)||-8.58|
Cellular Biomedicine Group has lower revenue, but higher earnings than Twist Bioscience. Cellular Biomedicine Group is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Twist Bioscience and Cellular Biomedicine Group, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Biomedicine Group||0||1||2||0||2.67|
Twist Bioscience presently has a consensus target price of $25.99, suggesting a potential downside of 9.13%. Cellular Biomedicine Group has a consensus target price of $32.00, suggesting a potential upside of 82.86%. Given Cellular Biomedicine Group’s higher probable upside, analysts clearly believe Cellular Biomedicine Group is more favorable than Twist Bioscience.
Insider & Institutional Ownership
22.7% of Twist Bioscience shares are held by institutional investors. Comparatively, 9.2% of Cellular Biomedicine Group shares are held by institutional investors. 9.1% of Cellular Biomedicine Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Twist Bioscience beats Cellular Biomedicine Group on 6 of the 11 factors compared between the two stocks.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company was founded in 2013 and is headquartered in San Francisco, California.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.